… cholesterol (LDL-C) and to reduce the risk of major adverse cardiovascular events. In
particular, evolocumab is a fully human monoclonal antibody directed toward the PCSK9 protein …

… We included patients with documented coronary artery disease (CAD) at baseline in FOURIER
(n = 23,656) in these analyses. Patients were stratified based on the presence of residual …

… 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with …
We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and …

… in Subjects With Elevated Risk (FOURIER) trial, in which 27 564 patients with atherosclerotic
cardiovascular disease treated with a statin were randomized to evolocumab vs placebo. …

… Conclusions and Relevance The addition of the PCSK9 inhibitor evolocumab to statin
therapy improved clinical outcomes, with significant reductions in total PEP events, driven by …

… restoration of all clinical outcomes from the FOURIER trial is required. Meanwhile, clinicians
should be sceptical about benefits versus harms of prescribing evolocumab for patients with …

… evolocumab significantly reduced cardiovascular events in patients with atherosclerotic
cardiovascular disease and metabolic syndrome without an increase in serious safety events, …

… evolocumab to statin therapy in patients with established ASCVD reduces the risk of developing
complex coronary artery disease … The benefits of evolocumab tended to increase over …

… clinical outcomes (21), the neutral effect of evolocumab on CRP levels found herein as well
as in previous trials points to the potential added value of combining PCSK9 antibodies with …

… evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular
outcome … blind trial, comparing evolocumab with placebo in 27,564 patients with atherosclerotic …